

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions and listings of the claims in this application.

**LISTING OF THE CLAIMS:**

1-175 (Canceled).

176 (Currently Amended) A liposome having a gel-phase bilayer membrane, comprising:  
an active agent selected from the group consisting of a pharmacologically active agent, a therapeutic agent, ~~a flavor agent~~, a diagnostic or imaging agent, ~~a nutritional agent~~, and combinations thereof,

wherein the gel-phase bilayer has a phase transition temperature of 39 to 45°C, and wherein the gel-phase lipid bilayer membrane comprises:

- (a) a first component which is dipalmitoylphosphatidylcholine (DPPC) in an amount ranging from 80 to 98 mol %; and
- (b) a second component selected from the group consisting of monostearoylphosphatidylcholine (MSPC) and monopalmitoylphosphatidylcholine (MPPC) in an amount ranging from 2 to 20 mol%.

177 (Previously Presented): The liposome of claim 176, wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methylprednisone, and navalbene.

178 (Previously Presented): The liposome of claim 177, wherein said active agent is paclitaxel.

179 (Previously Presented): The liposome of claim 177, wherein said active agent is camptothecin.

180 (Previously Presented): The liposome of claim 177, wherein said active agent is doxorubicin.

181 (Previously Presented): The liposome of claim 176, wherein said active agent is a non-steroidal anti-inflammatory agent.

182 (Previously Presented): The liposome of claim 181, wherein said active agent is ibuprofen.

183 (Currently Amended): A liposome having a gel-phase bilayer membrane, comprising:

an active agent selected from the group consisting of a pharmacologically active agent, a therapeutic agent, a flavor agent, a diagnostic or imaging agent, a nutritional agent, and combinations thereof,

wherein the gel-phase bilayer has a phase transition temperature of 39 to 45 °C, and wherein the gel-phase lipid bilayer membrane comprises:

(a) a first component which is dipalmitoylphosphatidylcholine (DPPC) in an amount ranging from 80 to 98 mol %; and

(b) a second component selected from the group consisting of:

(i) monostearoylphosphatidylcholine (MSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethyleneglycol) 2000] (DSPE-PEG-2000) in an amount ranging from 2 to 20 mol%; and

(ii) monopalmitoylphosphatidylcholine (MPPC) and 1,2-distearoyl-sn-

glycero-3-phosphoethanolamine-N-[poly(ethyleneglycol) 2000] (DSPE-PEG-2000) in an amount ranging from 2 to 20 mol%.

184 (Previously Presented): The liposome of claim 183, wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methylprednisone, and navalbene.

185 (Previously Presented): The liposome of claim 184, wherein said active agent is paclitaxel.

186 (Previously Presented): The liposome of claim 184, wherein said active agent is camptothecin.

187 (Previously Presented): The liposome of claim 184, wherein said active agent is doxorubicin.

188 (Previously Presented): The liposome of claim 183, wherein said active agent is a non-steroidal anti-inflammatory agent.

189 (Previously Presented): The liposome of claim 188, wherein said active agent is ibuprofen.